This is the third competing continuation application for the Cancer Center Support Grant at Vanderbilt lngram Cancer Center (VICC). VICC is a matrix center within Vanderbilt University Medical Center (VUMC) that integrates the cancer-related expertise and resources of the Schools of Medicine, Nursing, Arts and Sciences, Engineering;Peabody School of Education and the fully integrated Veterans Administration Medical Center. Most facilities are located on one campus, which promotes interactions, sharing of resources, and collaborations. Established in 1993, VICC functions as an organizational unit with a supra-departmental status. VICC-specific authorities and responsibilities are: 1) to conduct, coordinate and integrate cancer-related activities of Vanderbilt University;2) to carry out, support and enhance cancer research throughout the University;3) to develop, manage, and provide cancer education programs;and 4) to coordinate and integrate the care of cancer patients at VUMC. The research objectives are accomplished through seven research programs, two of which evolved out of previous programs and are considered new since the previous application. The programs are: Host-Tumor Interactions, Signal Transduction and Cell Proliferation, Genome Maintenance (new), Gastrointestinal Cancer, Thoracic/Head &Neck Cancer (new), Breast Cancer, and Cancer Epidemiology, Prevention and Control. Thirteen shared resources are proposed, 11 previously supported and two new. There has been remarkable VICC growth and accomplishments over the past project period. VICC has been awarded 11 new multi-investigator and six new training grants. In addition, we successfully renewed all three NCI SPOREs as well as eight multi-investigator and 11 training grants. With these and many other NCI grants, we increased our NCI funding by 62%. Significant investments have been made in cancer drug discovery, personalized cancer medicine, cancer epidemiology prevention and control, genomics, proteomics, informatics, bioinformatics, diversity initiatives, and cancer health disparities. Increased VICC space and facilities, along with philanthropic and institutional funds, supported the recruitment of 66 new faculty, who join a dedicated team carrying out the VICC mission: to alleviate cancer death and suffering through pioneering research, innovative clinical trials, evidence-based patient-care, prevention, education, and community activities.

Public Health Relevance

The Vanderbilt-lngram Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical and population-based research relevant to our mission to alleviate cancer death and suffering through pioneering research, innovative patient care, evidence-based prevention, education and communication. Our vision is to be a preeminent cancer center in the Southeast and a recognized leader, nationally and globally in the effort to prevent and treat cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-15
Application #
8141440
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-17
Project End
2015-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
15
Fiscal Year
2011
Total Cost
$5,898,751
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Vierra, Nicholas C; Dickerson, Matthew T; Jordan, Kelli L et al. (2018) TALK-1 reduces delta-cell endoplasmic reticulum and cytoplasmic calcium levels limiting somatostatin secretion. Mol Metab 9:84-97
Schlegel, Cameron; Weis, Victoria G; Knowles, Byron C et al. (2018) Apical Membrane Alterations in Non-intestinal Organs in Microvillus Inclusion Disease. Dig Dis Sci 63:356-365
Lewis Jr, James S; Shelton, Jeremy; Kuhs, Krystle Lang et al. (2018) p16 Immunohistochemistry in Oropharyngeal Squamous Cell Carcinoma Using the E6H4 Antibody Clone: A Technical Method Study for Optimal Dilution. Head Neck Pathol 12:440-447
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Heaster, Tiffany M; Walsh, Alex J; Zhao, Yue et al. (2018) Autofluorescence imaging identifies tumor cell-cycle status on a single-cell level. J Biophotonics 11:
PiƱeros, Marion; Frech, Silvina; Frazier, Lindsay et al. (2018) Advancing Reliable Data for Cancer Control in the Central America Four Region. J Glob Oncol :1-11
Schulte, Michael L; Fu, Allie; Zhao, Ping et al. (2018) Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 24:194-202
Petersen, Christine P; Meyer, Anne R; De Salvo, Carlo et al. (2018) A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut 67:805-817
Maacha, Selma; Hong, Jun; von Lersner, Ariana et al. (2018) AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking. Neoplasia 20:1008-1022
Galligan, James J; Wepy, James A; Streeter, Matthew D et al. (2018) Methylglyoxal-derived posttranslational arginine modifications are abundant histone marks. Proc Natl Acad Sci U S A 115:9228-9233

Showing the most recent 10 out of 2462 publications